Clinical Trials

388 enrolled

Phase NA Not yet recruiting

Breast Neoplasms

NCT07413146 2026-02-17

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

100 enrolled

Colonic Neoplasms, Neoplasm, Residual

NCT02662504 2026-02-05

MesoPDT

Other solid neoplasmThoracic

6 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT03748485 2026-01-28

CANWATCH

Phase NA Recruiting

650 enrolled

Colorectal Neoplasms

NCT03567889 2025-12-17

NeoDREAM

186 enrolled

Dermatologic

Melanoma

NCT05595408 2025-12-09

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

Recruiting

84 enrolled

Tumor-Agnostic

Neoplasm, Residual

NCT06052332 2025-12-05

SHAPERS

Phase NA Recruiting

230 enrolled

Rectal Neoplasms

NCT04567420 2025-10-16

DARE

Phase 2 Recruiting

70 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07188025 2025-09-23

REACT

103 enrolled

GastrointestinalGynecologic

Rectal Neoplasms

NCT00766142 2025-08-29

COCHISE

Phase 2 Terminated

18 enrolled 9 charts

Colonic Neoplasms, Peritoneal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04747145 2025-08-21

Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma

Phase 2 Active not recruiting

38 enrolled

CNS

Glioblastoma

NCT07089199 2025-07-28

TitAN

34 enrolled

Thoracic

NSCLC

NCT07067268 2025-07-16

Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

Phase 2 Recruiting

76 enrolled

Nasopharyngeal Carcinoma

NCT00354393 2025-07-15

Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma

Other solid neoplasmThoracic

9 enrolled

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT06914440 2025-07-15

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer

Phase 2 Recruiting

27 enrolled

Phase NA Active not recruiting

Breast Neoplasms

NCT02401685 2025-07-10

POSNOC

1,900 enrolled

Breast Neoplasms

NCT01815853 2025-07-03

Neo-CRAG

620 enrolled

Stomach Neoplasms

NCT06646445 2025-06-13

PREMICES

60 enrolled

Turcot syndrome, Colonic Neoplasms, Microsatellite Instability

NCT00667069 2025-06-05

Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer

Phase 3 Not yet recruiting

424 enrolled

Genitourinary

Prostatic Neoplasms

NCT06996093 2025-05-30

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

2,508 enrolled

Breast Neoplasms

NCT06942663 2025-04-24

JAGC1

228 enrolled

Stomach Neoplasms

NCT06476119 2025-04-23

OPTImaL

Recruiting

490 enrolled

Phase NA Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03789682 2025-04-16

CD155 in Bladder Cancer

Completed

151 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT01817192 2025-04-13

Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

420 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04517214 2025-04-02

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

100 enrolled

Nasopharyngeal Carcinoma

NCT00059930 2025-03-26

Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer

Phase 1 Completed

38 enrolled

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT02395367 2025-03-07

POROMS

Completed

30,000 enrolled

Head and Neck Neoplasms, Postoperative Complications

NCT00544414 2025-02-19

Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer

31 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00667121 2025-02-14

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Completed

88 enrolled

Breast Neoplasms, Depression, Hot Flashes

NCT00559156 2025-02-13

Arginine/Omega-3 Fatty Acids/Nucleotides Nutritional Supplement in Treating Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

46 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms

NCT06427447 2025-02-04

ADJUPANC

770 enrolled

Pancreatic Neoplasms

NCT06792149 2025-01-24

Prediction of Drug Response in Gastric Cancer Based on 3D Bioprinting

Recruiting

60 enrolled

Stomach Neoplasms

NCT06775652 2025-01-15

ESCC

254 enrolled

Esophageal Squamous Cell Carcinoma

NCT05456165 2024-12-31

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

Phase 2 Withdrawn

Phase 2 Active not recruiting

Colonic Neoplasms, Colorectal Neoplasms

NCT02124421 2024-11-19

CRS/HIPEC

32 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03228043 2024-11-14

Apatinib for Resectable Colorectal Cancer

Phase NA Withdrawn

Colorectal Neoplasms

NCT03673072 2024-11-12

GAIN

68 enrolled

Biliary Tract Neoplasms

NCT06520683 2024-11-07

SMALLER

180 enrolled

Colorectal Neoplasms

NCT03308591 2024-10-31

Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients

774 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05496491 2024-10-08

Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial

Phase NA Recruiting

84 enrolled

Neoplasms, Rectal Neoplasms

NCT06609551 2024-09-24

ZJCH-CRCC-1

312 enrolled